Overview

Safety Assessment of P2Et Extract in Healthy Voluntary Subjects in Colombia

Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Caesalpinia spinosa extract is rich in gallotannins and other well characterized polyphenols and has a major antioxidant activity. The extract shows immunomodulatory activity in healthy animals and anti-tumor activity in animals with breast cancer and melanoma as well. The use of P2Et in animals with tumors shows a synergistic effect with doxorubicin in drug-resistant cell lines. In addition, an increase in survival of transplanted animals with a TS/A breast cancer tumor model and treated with P2Et, in conjunction with calreticulin increase is observed. This open-label, single arm, Phase 1 study intends to assess the safety of P2Et extract obtained from Caesalpinia spinosa, with dose escalation, in healthy voluntary participants in Colombia.
Phase:
Phase 1
Details
Lead Sponsor:
Hospital Universitario San Ignacio
Collaborator:
Pontificia Universidad Javeriana